These results are in concordance with the previously published study showing elevated glycolysis and increased OXPHOS in an in vivo model of myeloproliferative neoplasms driven by JAK2-activating mutation.13 Surprisingly, we observed that PAX5-JAK2-transformed cells change their metabolism in an opposite manner, that is, they lower their glycolytic and respiratory functions. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.